Denise M. Visco

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 456 citations · Full text

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 426 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Active Cyclooxygenase-2 Inhibitor +10

Gene deletion of either interleukin‐1β, interleukin‐1β–converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy

Kristen M. Clements, Joanne S. Price, M.G. Chambers et al. · Arthritis & Rheumatism · 2003 · 211 citations

The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the dog

James L. Cook, Keiichi Kuroki, Denise M. Visco et al. · Osteoarthritis and Cartilage · 2010 · 210 citations

Anterior (cranial) cruciate ligament transection in the dog: a bona fide model of osteoarthritis, not merely of cartilage injury and repair.

K D Brandt, Ethan M. Braunstein, Denise M. Visco et al. · PubMed · 1991 · 206 citations

Gait Analysis, Unstable Knee, Surgery +18